Leptomeningeal Disease clinical trials at UCSF

1 in progress, 0 open to eligible people

Showing trials for

  • Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD

    Sorry, in progress, not accepting new patients

    A phase 2 non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab with capecitabine for the treatment of leptomeningeal metastases in HER2-neu positive breast cancer.

    San Francisco, California and other locations

Our lead scientists for Leptomeningeal Disease research studies include .

Last updated: